NCT05462041

Brief Summary

The purpose the research is to evaluate whether patients who receive a Donation after Circulatory Death (DCD) heart for cardiac transplantation using either normothermic regional perfusion (NRP) or direct procurement and perfusion (DPP) have similar outcomes as patients who receive Donation after Brain Death (DBD) heart using standard cold storage. The study will also evaluate whether DCD procured hearts have a meaningful impact on hearts available for transplantation at our center.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started May 2022

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 24, 2022

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

July 14, 2022

Completed
4 days until next milestone

First Posted

Study publicly available on registry

July 18, 2022

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2024

Completed
1.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

April 18, 2025

Status Verified

April 1, 2025

Enrollment Period

2.3 years

First QC Date

July 14, 2022

Last Update Submit

April 16, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Evaluate the safety of utilizing DCD donor hearts as compared to DBD donor hearts for transplantation.

    Percentage of subjects with incidence of heart graft-related Serious Adverse Events (HGRSAEs) in the DCD Heart Transplanted Recipient Population

    30 days post-heart transplant

Secondary Outcomes (1)

  • Assess the practical, financial and logistical viability of using NRP vs. DPP for the procurement of DCD donor hearts.

    1 year

Study Arms (2)

DBD Donor Heart Transplantation

OTHER

If the heart offer is from a DBD donor, the heart will be retrieved per standard of care.

Other: DBD Donor Heart Transplantation

DCD Donor Heart Transplantation

OTHER

If the heart offer is from a DCD donor, the heart will be retrieved using one of two strategies: Normothermic Regional Perfusion (NRP) or Direct Procurement and Perfusion (DPP). NRP procedures will be used to procure all DCD hearts unless contraindicated or prohibited by the donor hospital. In the event the donor hospital does not allow NRP for cardiac organ procurement, or the target number of eight DCD transplants with NRP has been achieved, DPP with the Organ Care System (OCS) should be utilized.

Device: DCD Donor Heart Transplantation

Interventions

A technique of donor heart procurement.

DBD Donor Heart Transplantation

A technique of donor heart procurement. The TransMedics' OCS Heart technology is the only portable system available for ex-vivo maintenance of the donor heart in a metabolically active and beating state. It is currently FDA approved for procurement and transport.

DCD Donor Heart Transplantation

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subjects must be willing and be capable of understanding the purpose and risks of the study and must sign a statement of informed consent OR consent of a legally authorized representative of a cognitively impaired individual will be obtained before the cognitively impaired individual may be included in research.
  • Signed: 1) written informed consent document and 2) authorization to use and disclose protected health information
  • Male or female, aged 18 years of age or older listed for primary heart transplant

You may not qualify if:

  • Prior history of cardiac transplantation
  • Multi-organ transplant
  • Current or planned participation in another interventional trial
  • Recipient has any condition that, in the opinion of the Investigator, would make study participation unsafe or would interfere with the objectives of the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cedars Sinai Medical Center

Los Angeles, California, 90048, United States

Location

Study Officials

  • Fardad Esmailian, MD

    Cedars-Sinai Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Surgical Director, Heart Transplantation and Mechanical Circulatory Support

Study Record Dates

First Submitted

July 14, 2022

First Posted

July 18, 2022

Study Start

May 24, 2022

Primary Completion

August 31, 2024

Study Completion

December 31, 2025

Last Updated

April 18, 2025

Record last verified: 2025-04

Locations